Eisai's Halaven now available in Russia for advanced breast cancer
Halaven (eribulin) manufactured by Japanese drug major Eisai (TYO: 4523) is now available in Russia. It is indicated to treat patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease.
The new indication for the drug comes after marketing authorization approval for earlier use in advanced disease from the European Commission in July 2014, based on clinical evidence from two Phase III trials, EMBRACE and study 301, which involved more than 1,800 patients. The EMBRACE trial showed eribulin could prolong median overall survival in heavily pre-treated women compared to women receiving an alternative treatment of physician’s choice by 2.7 months.
In Russia, breast cancer is the most common cause of death in women aged 45-55 years, and that has increased by 64% over the last 20 years alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze